( † Disclaimer: This search is powered by PubMed, a service of the U.S. National Library of Medicine. PubMed is a third-party website with no affiliation with Cleveland Clinic.)

Biographical Sketch

Mina K. Chung, MD, is a Staff Cardiologist in the Section of Pacing and Electrophysiology, The Robert and Suzanne Tomsich Department of Cardiovascular Medicine, at Cleveland Clinic. Dr. Chung is board-certified in internal medicine and in the subspecialties of cardiovascular disease and clinical cardiac electrophysiology, which is her specialty interest.

Dr. Chung did her undergraduate work at the University of California at San Diego, graduating with a major in chemistry, and she was inducted into Phi Beta Kappa, the national honor society. She received her medical degree from Washington University School of Medicine in St. Louis, where she completed her internship and residency in internal medicine at the Jewish Hospital of the Washington University School of Medicine, becoming Chief Resident. She received fellowships in research and in cardiology from the Jewish Hospital, followed by a fellowship in cardiac electrophysiology from Barnes Hospital, Washington University School of Medicine, during which she received the Michael Bilitch Fellowship Award in Cardiac Pacing and Electrophysiology from the North American Society of Pacing and Electrophysiology.

Dr. Chung has been principal investigator or co-investigator in a number of important clinical trials studying atrial fibrillation, supraventricular and ventricular arrhythmias, cardioversion, pacemaker and defibrillator therapy, biventricular pacing for heart failure and catheter ablation approaches. Along with colleagues at Cleveland Clinic, she reported the first association of inflammation with persistence of atrial fibrillation. She has also been a Principal Investigator for AFFIRM (Atrial Fibrillation Follow-up Investigation of Rhythm Management), a multicenter randomized trial of rate-control versus rhythm-control strategies for atrial fibrillation. In this study, she has led analyses that demonstrate functional status benefits that help to justify and rationalize maintenance of sinus rhythm in patients with symptomatic atrial fibrillation. She is also investigating the genetics of arrhythmias, including atrial fibrillation. Dr. Chung has been an invited lecturer to numerous national conferences to present findings from her research.

Her published articles have appeared in many scientific and professional journals including Circulation, Journal of the American College of Cardiology, Pacing and Clinical Electrophysiology, American Journal of Cardiology, Proceedings of the National Academy of Sciences, Annals of Internal Medicine, Annals of Thoracic Surgery, and Nature Genetics. She has authored multiple chapters in medical textbooks related to her specialty interest and published numerous abstracts. She is a reviewer of abstracts for the North American Society of Pacing and Electrophysiology, the American College of Cardiology and the American Heart Association.

Dr. Chung is a Fellow in the American College of Cardiology, in the Heart Rhythm Society and in the Council on Clinical Cardiology of the American Heart Association. She was named in Best Doctors in America, 2001 through 2011.

Industry Relationships

Cleveland Clinic physicians and scientists may collaborate with the pharmaceutical or medical device industries to help develop medical breakthroughs or provide medical expertise or education. Cleveland Clinic strives to make scientific advances that will benefit patient care and support outside relationships that promise public benefit. In order for the discoveries of Cleveland Clinic physicians' and scientists' laboratories and investigations to benefit the public, these discoveries must be commercialized in partnership with industry. As experts in their fields, Cleveland Clinic physicians and scientists are often sought after by industry to consult, provide expertise and education.

To assure professional and commercial integrity in such matters, Cleveland Clinic maintains a program that reviews these collaborations and, when appropriate, puts measures in place to minimize bias that may result from ties to industry. The Cleveland Clinic publicly discloses the names of companies when (i) its physicians/scientists receive $5,000 or more per year (or, in rare cases, equity or stock options) for speaking and consulting, (ii) its physicians/scientists serve as a fiduciary, (iii) its physicians/scientists
receive or have the right to receive royalties or (iv) its physicians/scientists hold any equity interest for the physician's/scientist's role as inventor, discoverer, developer, founder or consultant.* In publicly disclosing this information, the Cleveland Clinic tries to provide information as accurately as possible about its physicians' and scientists' connections with industry.

As of 6/25/2014, Dr. Chung has reported no financial relationship with industry that is applicable to this listing. In general, patients should feel free to contact their doctor about any of the relationships and how the relationships are overseen by the Cleveland Clinic. To learn more about the Cleveland Clinic's policies on collaborations with industry and innovation management, go to our Integrity in Innovation page.

Public Health Service-Reportable Financial Conflicts of Interest. Cleveland Clinic scientists and physicians engage in basic, translational and clinical research activities, working to solve health problems, enhance patient care and improve quality of life for patients. Interactions with industry are essential to bringing the researchers’ discoveries to the public, but can present the potential for conflicts of interest related to their research activities. Click here to view a listing of instances where Cleveland Clinic has identified a Public Health Service (PHS)-Reportable Financial Conflict of Interest and has put measures in place to ensure that, to the extent possible, the design, conduct and reporting of the research is free from bias.

* Cleveland Clinic physicians and scientists subscribe to the guidance presented in the PhRMA Code on Interactions with Healthcare Professionals and the AdvaMed Code of Ethics on Interactions with Health Care Professionals. As such, gifts of substantial value are generally prohibited.